International trade · 01/02/2011Updated: 10/17/2026 · 1 min read
U.S. Patent Office Grants Interim Extension to MEDIASANTE Biosciences' MIFAMURTIDE Patent
Summary
The U.S. Patent and Trademark Office has granted a fourth one-year interim extension to the term of U.S. Patent No. 4,971,802, covering MEDIASANTE Biosciences' MIFAMURTIDE, a treatment for multiple myeloma.
Original source language: Federal Register — Department of CommerceOpen original release →